369 related articles for article (PubMed ID: 24810355)
1. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
Lee YM; Kim YH; Han DJ; Park SK; Park JS; Sung H; Hong HL; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Lee SO
Transpl Infect Dis; 2014 Jun; 16(3):397-402. PubMed ID: 24810355
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.
Watcharananan SP; Louhapanswat S; Chantratita W; Jirasiritham S; Sumethkul V
Transplant Proc; 2012 Apr; 44(3):701-5. PubMed ID: 22483472
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
5. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
6. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.
Gómez E; Laurés A; Baltar JM; Melón S; Díez B; de Oña M
Transplant Proc; 2005 Nov; 37(9):3760-3. PubMed ID: 16386530
[TBL] [Abstract][Full Text] [Related]
8. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
13. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
14. Influence of cytomegalovirus disease in outcome of solid organ transplant patients.
Linares L; Sanclemente G; Cervera C; Hoyo I; Cofán F; Ricart MJ; Pérez-Villa F; Navasa M; Marcos MA; Antón A; Pumarola T; Moreno A
Transplant Proc; 2011; 43(6):2145-8. PubMed ID: 21839217
[TBL] [Abstract][Full Text] [Related]
15. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
16. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
19. Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study.
Los-Arcos I; Len O; Perello M; Torres IB; Codina G; Esperalba J; Sellarés J; Moreso F; Seron D; Gavaldà J
J Clin Virol; 2019 Jan; 110():45-50. PubMed ID: 30537648
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
